Chiesi has taken the lead in making an upfront investment in a new platform of inhalers, called the carbon minimal inhalers, ...

The Medtech sector is at a critical moment, where innovation and regulation must coexist. A stricter regulatory environment ...

The antibody-drug conjugate (ADC) is currently under review by the FDA as a treatment for advanced or metastatic non-squamous ...

In final draft guidance due to be finalised before the end of the month, Welireg (belzutifan) has been recommended as an ...

MSD's PD-1 inhibitor Keytruda has ruled the immunotherapy of non-small cell lung cancer (NSCLC) for many years, but a ...

MSD and Daiichi Sankyo started enrolling patients into the phase 3 Ideate-Lung02 study in the summer.